The formal evidence-based indication from the Global Consensus statement is limited to hypoactive sexual desire disorder in postmenopausal women; trials in premenopausal or perimenopausal women are too sparse to support a formal recommendation there.
That said, the ISSWSH clinical practice guideline notes that limited data also support use in late reproductive-age premenopausal women, and some field experts report using testosterone in perimenopausal patients for desire, arousal, orgasm and satisfaction based on clinical experience. If you're considering this in perimenopause, it's worth knowing you are one step further from the core evidence base than a postmenopausal woman using the same treatment, which is a reasonable thing to discuss openly with whoever is prescribing.
This is a genuine, acknowledged gap between the formal evidence-based indication, which is postmenopausal only, and a documented, more permissive allowance in a specialty guideline plus real field practice extending use into perimenopause.
What the research shows, and which source each finding rests on
The Global Consensus Position Statement limits the evidence-based indication for testosterone therapy to postmenopausal HSDD; trials in premenopausal women are too sparse to support the same conclusion.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Evidence-based indication is postmenopausal only
Global Consensus Position Statement (Davis et al.)
The trial base supporting testosterone's benefit is built almost entirely on postmenopausal women; premenopausal and perimenopausal trial data are too sparse to formally extend the indication.
Limited data and field practice support earlier use
ISSWSH guideline; Rachel Rubin, MD, clinical practice
The ISSWSH guideline itself notes limited supporting data in late reproductive-age premenopausal women, and Rubin reports in interviews that there is also data in perimenopausal women showing benefit for libido, arousal, orgasm and satisfaction.
What would settle it: Dedicated randomized trials in perimenopausal women with diagnosed HSDD would settle whether the postmenopausal evidence generalizes to this earlier stage.
What is really going on here
- If I start testosterone in perimenopause, what dose, what target level, and how does the evidence for me differ from a postmenopausal woman?
Questions for your doctor
- Given that I'm still perimenopausal, how does the evidence for testosterone differ for me?
- Would it make sense to wait, or is there a reason to consider it now?
- What monitoring plan would you use given the less-established evidence at this stage?
- What are realistic expectations for benefit at this point in my transition?
Questions with no answer yet
Is testosterone's benefit for desire, arousal, orgasm, and satisfaction, well established in postmenopausal women, actually the same in perimenopausal women, or could the very different hormonal environment of perimenopause, fluctuating rather than uniformly low estrogen, change how testosterone behaves?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: This is the single most clearly identified gap in the underlying evidence base: almost every trial testing testosterone in women was conducted in postmenopausal women, and the formal evidence-based indication is limited to that population specifically because premenopausal and perimenopausal trial data are too sparse to support the same conclusion. No dedicated trial has tested whether the postmenopausal findings simply generalize to a hormonally fluctuating perimenopausal state.
What would test it: Dedicated randomized trials in perimenopausal women with diagnosed low desire, using the same rigor as the existing postmenopausal trials.
Are perimenopausal women whose care includes testosterone at meaningfully higher risk than postmenopausal women, given that dosing standards and monitoring protocols were developed and tested in postmenopausal patients?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The field standard for dosing, monitoring, and target levels comes from postmenopausal research and guideline development, without a dedicated safety study establishing whether the same dosing and monitoring approach is equally safe when applied to a perimenopausal woman's different underlying hormonal state.
What would test it: A dedicated safety and monitoring study of testosterone use specifically in perimenopausal women, rather than extrapolating postmenopausal safety data.
Is my low testosterone actually low compared with what women's bodies were meant to have, before modern life changed everything?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: This is a genuine data-free zone for women specifically. Research on androgen levels in subsistence and pre-industrial populations is almost entirely about men, and no study has directly compared women's testosterone across subsistence and industrialized populations. The nearest evidence, for a different but related hormone system, actually points the opposite direction to what the question assumes: where estradiol and progesterone have been compared across populations, women in wealthier, industrialized settings run higher, not lower, than women in physically demanding, energy-limited settings.
What would test it: A single, consistent hormone-panel study measuring testosterone across matched subsistence and industrialized female populations of the same ages, using one laboratory and one measurement method, which does not currently exist.
Sources
- 1.Global Consensus Position Statement on the Use of Testosterone Therapy for Women.Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab 2019;104(10):4660-4666 · Systematic review or guideline
- 2.International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.Parish SJ, Simon JA, Davis SR, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for HSDD in Women. J Sex Med 2021;18(5):849-867 · Systematic review or guideline
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- What is GSM (genitourinary syndrome of menopause) and why does it affect both my vagina and my bladder?
- Is vaginal estrogen safe, and what happened to that scary warning label about stroke and cancer?
- Can I use vaginal estrogen if I've had breast cancer?
- I keep getting UTIs after menopause and keep getting put on antibiotics - can vaginal estrogen actually help?
- Sex has become painful since perimenopause - is this just something I have to live with?
- What is vaginal DHEA (prasterone) and how is it different from vaginal estrogen?
- Back to topic: Vaginal, sexual and urinary health